home / stock / calt / calt news

CALT News and Press, Calliditas Therapeutics AB From 05/30/23

Stock Information
Company Name: Calliditas Therapeutics AB
Stock Symbol: CALT
Market: NASDAQ
Menu
CALT CALT Quote CALT Short CALT News CALT Articles CALT Message Board
Get CALT Alerts

News, Short Squeeze, Breakout and More Instantly...
CALT - Calliditas Q1 Earnings: Buy The Dip On This GARP Commercial Biotech

2023-05-30 06:54:18 ET Summary Patient and Prescriber Uptick: Despite Q1 2023's slightly disappointing earnings, Tarpeyo saw robust growth in new patient enrollments and prescriber numbers. Competitive Edge: Recent Phase 3 DUPLEX FSGS readout from Travere showing non-stat signific...
CALT - Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023

2023-05-16 18:55:18 ET Summary HSCT-TMA BLA Resubmission: Omeros plans to resubmit a BLA for narsoplimab, potentially gaining approval by Q2 2024. IgAN Trial Progress: Top-line results for the phase 3 ARTEMIS trial on narsoplimab for IgAN are expected in Q3 2023. Solid Financi...

CALT - Phio, Coya top healthcare gainers; Eloxx, Modular Medical among losers

2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...

CALT - Calliditas Therapeutics: Interim Report Q1, 2023

Calliditas Therapeutics: Interim Report Q1, 2023 PR Newswire STOCKHOLM , May 16, 2023 /PRNewswire/ -- Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its prim...
CALT - Calliditas: A Trailblazing Triumph In IgAN Treatment

2023-04-27 09:17:35 ET Summary Part B portion of Phase 3 NefIgArd trial reveals positive outcomes for nefecon, leading to a reaffirmed buy recommendation for Calliditas. Nefecon demonstrates statistically significant stabilization of eGFR levels in IgAN patients, with consistent b...

CALT - Calliditas Therapeutics' 2022 Annual Report Published

Calliditas Therapeutics' 2022 Annual Report Published PR Newswire STOCKHOLM , April 26, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's websi...

CALT - Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales

2023-04-12 06:34:14 ET Summary Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confirmed the previous positive findings from the phase 3 trial and indicate a potential disease-modifying...
CALT - Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) ...

CALT - Everest's kidney disease drug Nefecon gets review in Singapore

2023-04-06 05:40:50 ET Singapore's Health Sciences Authority (HSA) accepted to review Everest Medicines' application seeking approval of Nefecon to treat primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. The company expects to get approval of the...

CALT - Calliditas to participate in upcoming investor conferences

Calliditas to participate in upcoming investor conferences PR Newswire STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following i...
Previous 10 Next 10